Certara Showcases 2024 Research Wins With Over 100 Papers Published
Certara (Nasdaq: CERT) highlights its 2024 research achievements with over 100 publications and recognition of 12 company scientists in the Stanford/Elsevier top 2% cited researchers list. The publications cover diverse areas including pediatric oncology, first-in-human dose predictions, exposure-response analyses, and the application of PBPK modeling in global health. Notable research trends focused on biosimulation strategies in drug development and extended model-informed drug development, including the implementation of generative AI in regulatory writing and diversity in clinical trial enrollment.
Certara (Nasdaq: CERT) mette in evidenza i suoi risultati di ricerca del 2024 con oltre 100 pubblicazioni e il riconoscimento di 12 scienziati dell'azienda nella lista dei primi 2% di ricercatori citati di Stanford/Elsevier. Le pubblicazioni coprono diverse aree tra cui oncologia pediatrica, previsioni di dosaggio per i primi trattamenti sull'essere umano, analisi esposizione-risposta e l'applicazione della modellazione PBPK nella salute globale. Tra le tendenze di ricerca più significative si sono concentrate sulle strategie di biosimulazione nello sviluppo dei farmaci e sullo sviluppo di farmaci informato dai modelli estesi, inclusa l'implementazione dell'IA generativa nella scrittura regolatoria e la diversità nell'arruolamento di trial clinici.
Certara (Nasdaq: CERT) destaca sus logros de investigación de 2024 con más de 100 publicaciones y el reconocimiento de 12 científicos de la empresa en la lista de los investigadores más citados del 2% de Stanford/Elsevier. Las publicaciones abarcan diversas áreas, incluyendo oncología pediátrica, predicciones de dosis en humanos primeros, análisis de exposición-respuesta y la aplicación de modelado PBPK en la salud global. Las tendencias de investigación notables se centraron en estrategias de biosimulación en el desarrollo de medicamentos y el desarrollo de medicamentos informado por modelos extendidos, incluida la implementación de inteligencia artificial generativa en la redacción regulatoria y diversidad en la inscripción de ensayos clínicos.
Certara (Nasdaq: CERT)는 100편 이상의 출판물과 스탠포드/엘세비어의 상위 2% 인용 연구원 목록에 있는 12명의 회사 과학자들의 인정으로 2024년 연구 성과를 강조합니다. 출판물은 소아 종양학, 첫 인간 동물에 대한 용량 예측, 노출-반응 분석 및 글로벌 건강에서의 PBPK 모델링 적용 등 다양한 분야를 다룹니다. 주목할 만한 연구 동향은 약물 개발에서의 바이오 시뮬레이션 전략과 확대된 모델 정보 약물 개발에 집중되었으며, 규제 작성의 생성적 AI 구현과 임상 시험 등록의 다양성을 포함합니다.
Certara (Nasdaq: CERT) met en avant ses réalisations en recherche pour 2024 avec plus de 100 publications et la reconnaissance de 12 scientifiques de l'entreprise dans la liste des 2 % des chercheurs les plus cités par Stanford/Elsevier. Les publications couvrent divers domaines, notamment l'oncologie pédiatrique, les prévisions de doses pour les premiers traitements chez l'homme, les analyses exposition-réponse et l'application de la modélisation PBPK dans la santé mondiale. Parmi les tendances de recherche notables, on trouve des stratégies de biosimulation dans le développement de médicaments et le développement de médicaments informé par des modèles étendus, y compris l'implémentation de l'IA générative dans la rédaction réglementaire et la diversité dans le recrutement d'essais cliniques.
Certara (Nasdaq: CERT) hebt seine Forschungsergebnisse 2024 mit über 100 Veröffentlichungen und der Anerkennung von 12 Wissenschaftlern des Unternehmens in der Liste der am häufigsten zitierten Forscher im Obersten 2%-Bereich von Stanford/Elsevier hervor. Die Veröffentlichungen decken verschiedene Bereiche ab, darunter Pädiatrische Onkologie, Dosisvorhersagen für Erstbehandlungen am Menschen, Expositions-Reaktions-Analysen und die Anwendung von PBPK-Modellierung im globalen Gesundheitswesen. Zu den bemerkenswerten Forschungstrends gehörten Biosimulationsstrategien in der Arzneimittelentwicklung und die erweiterte modellinformierte Arzneimittelentwicklung, einschließlich der Implementierung generativer KI in der regulatorischen Dokumentation und der Diversität bei der Rekrutierung für klinische Studien.
- 12 company scientists recognized among top 2% most-cited researchers globally
- Over 100 scientific publications secured in 2024
- Broad research coverage across entire drug development process
- None.
The company celebrates the 12 scientists included in the Stanford/Elsevier top
RADNOR, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today showcases its impact on research by celebrating more than 100 publications secured in 2024 as well as the 12 Certara scientists included on the 2024 Stanford/Elsevier list, which highlights the top
Stanford/Elsevier's Top
Now in its 7th iteration, the Stanford/Elsevier's Top
- Amin Rostami-Hodjegan, Chief Scientific Officer at Simcyp
- Frederic Bois, Senior Scientific Advisor & Head of Mechanistic Modelling
- Hannah Jones, Senior Vice President, Head of Simcyp PBPK Modelling Services
- Hugo Geerts, Head of QSP Neurosciences
- Khaled Abduljalil, Senior Principal Scientist at Simcyp
- Karen Rowland-Yeo, Senior Vice President, Client & Regulatory Strategy
- Masoud Jamei, Senior Vice President of Research and Development at Simcyp
- Piet H van der Graaf, Senior Vice President and Head of Quantitative Systems Pharmacology
- Patrick Smith, President of Certara Drug Development Solutions
- Rajesh Krishna, Distinguished Scientist, Drug Development Science
- Stephen Duffull, Senior Scientific Advisor
- Trevor Johnson, Principal Scientist at Simcyp
"Certara is a science-driven organization, and our scientists are world leaders in their fields. Our clients rely on us to deliver advanced biosimulation software and the expert advice needed to interpret results for optimal strategic decision-making,” said William Feehery, CEO, Certara.
2024 Publications
Certara scientists and publications span the entire drug discovery and development process from early discovery through clinical, regulatory, and post-approval. Key highlights and trends evident in 2024 publications are grouped into two primary categories below.
Value and Impact of Biosimulation Strategies and Execution in Drug Development
- Pediatric oncology drug development and dosage optimization
- Mechanistic modeling’s impact on first-in-human dose predictions and clinical validations thereof
- Exposure-Response Analyses to Inform Dosing Considerations and Labeling
- Impact of physiologically-based pharmacokinetics (PBPK) modeling on Global Health
- The role of pharmacometrics in understanding Variability in Clinical Trials
- Extended Model-Informed Drug Development: Beyond Clinical Trials and Regulatory Approval
Best practices for implementing technologies that streamline drug submission and approval processes
- Diversity in Clinical Trial Enrollment and meeting requirements of the FDA Diversity Action Plan
- Using real-world data to inform clinical patient management and treatment guidelines for COVID-19
- Unlocking the Synergies of Generative AI in Regulatory Writing
- Preventing chaos: The Critical Role of the Submission Lead
To learn more about Certara’s publications, please visit: www.certara.com/resources/publication
About Certara
Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com.
Certara Contact:
Sheila Rocchio
sheila.rocchio@certara.com
Media Contact:
Alyssa Horowitz
certara@pancomm.com
FAQ
How many publications did Certara (CERT) secure in 2024?
How many Certara (CERT) scientists were included in the 2024 Stanford/Elsevier top 2% cited researchers list?
What are the main research areas covered in Certara's (CERT) 2024 publications?
